Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10